Summary of opinion: Supemtek Tetra (previously Supemtek), 27/02/2025 Positive
Submitted by Anonymous (not verified) on 28 February 2025 - 11:00
Summary of opinion: Supemtek Tetra (previously Supemtek), 27/02/2025 Positive
Summary of opinion: Prevymis, 27/02/2025 Positive
Submitted by Anonymous (not verified) on 28 February 2025 - 11:00
Summary of opinion: Prevymis, 27/02/2025 Positive
Summary of opinion: Enhertu, 27/02/2025 Positive
Submitted by Anonymous (not verified) on 28 February 2025 - 11:00
Summary of opinion: Enhertu, 27/02/2025 Positive
Summary of opinion: Fabhalta, 27/02/2025 Positive
Submitted by Anonymous (not verified) on 28 February 2025 - 11:00
Summary of opinion: Fabhalta, 27/02/2025 Positive
Summary of opinion: Rinvoq, 27/02/2025 Positive
Submitted by Anonymous (not verified) on 28 February 2025 - 11:00
Summary of opinion: Rinvoq, 27/02/2025 Positive
First topical gene therapy treatment for dystrophic epidermolysis bullosa
Submitted by Anonymous (not verified) on 28 February 2025 - 11:00
First topical gene therapy treatment for dystrophic epidermolysis bullosa
Summary of opinion: Stelara, 27/02/2025 Positive
Submitted by Anonymous (not verified) on 28 February 2025 - 11:00
Summary of opinion: Stelara, 27/02/2025 Positive
Summary of opinion: Imfinzi, 27/02/2025 Positive
Submitted by Anonymous (not verified) on 28 February 2025 - 11:00
Summary of opinion: Imfinzi, 27/02/2025 Positive
Summary of opinion: Kaftrio, 27/02/2025 Positive
Submitted by Anonymous (not verified) on 28 February 2025 - 11:00
Summary of opinion: Kaftrio, 27/02/2025 Positive
Combination of cystic fibrosis medicines to treat patients with rare mutations
Submitted by Anonymous (not verified) on 28 February 2025 - 11:00
Combination of cystic fibrosis medicines to treat patients with rare mutations